Literature DB >> 20479781

A case of variant angina in a patient under chronic treatment with sorafenib.

Italo Porto1, Andrea Leo, Luca Miele, Maurizio Pompili, Raffaele Landolfi, Filippo Crea.   

Abstract

BACKGROUND: A 63-year-old man with an unresectable multifocal hepatocellular carcinoma (HCC) presented with upper abdominal discomfort, nausea and vomiting. We report a case of variant angina in a patient affected by unresectable HCC under chronic treatment with sorafenib. Spontaneous spasm occurred during cardiac catheterization and was revealed during coronary angiogram with the unusual feature of a retrograde transient filling of a contralateral branch. INVESTIGATIONS: Electrocardiogram, cardiac catheterization, chest X-ray, emergency ECG. DIAGNOSIS: Variant angina induced by sorafenib treatment mimicking infero-posterior ST-elevation myocardial infarction (STEMI). MANAGEMENT: High-dose calcium-antagonists and nitrates were initially given intravenously and then orally. Sorafenib therapy was then resumed without further symptoms. Restaging of the cancer revealed unexpected local recurrence and the patient died 1 month after receiving palliative care. We contend that the effects of sorafenib treatment were primarily responsible for the major cardiovascular event observed in this case, and it is important for clinicians to be aware of this possible severe complication of sorafenib therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479781     DOI: 10.1038/nrclinonc.2010.67

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  25 in total

1.  Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts.

Authors:  Geraldine Pawlak; David M Helfman
Journal:  Mol Biol Cell       Date:  2002-01       Impact factor: 4.138

2.  Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure.

Authors:  R A de Boer; H J Siebelink; R A Tio; F Boomsma; D J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2001-06       Impact factor: 15.534

3.  Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100.

Authors:  Rebecca M Shepherd; Benjamin J Capoccia; Steven M Devine; John Dipersio; Kathryn M Trinkaus; David Ingram; Daniel C Link
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

4.  Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina.

Authors:  K Kugiyama; H Yasue; K Okumura; H Ogawa; K Fujimoto; K Nakao; M Yoshimura; T Motoyama; Y Inobe; H Kawano
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

Review 5.  Recent insights into the mechanisms, predisposing factors, and racial differences of coronary vasospasm.

Authors:  Kunihisa Miwa; Masatoshi Fujita; Shigetake Sasayama
Journal:  Heart Vessels       Date:  2005-02       Impact factor: 2.037

Review 6.  Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.

Authors:  Ming Hui Chen; Risto Kerkelä; Thomas Force
Journal:  Circulation       Date:  2008-07-01       Impact factor: 29.690

Review 7.  Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy.

Authors:  Aarif Y Khakoo; Edward T H Yeh
Journal:  Nat Clin Pract Oncol       Date:  2008-09-16

Review 8.  An overview of small-molecule inhibitors of VEGFR signaling.

Authors:  S Percy Ivy; Jeannette Y Wick; Bennett M Kaufman
Journal:  Nat Rev Clin Oncol       Date:  2009-09-08       Impact factor: 66.675

9.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Authors:  Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen
Journal:  Lancet       Date:  2007-12-15       Impact factor: 79.321

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  10 in total

1.  Sorafenib cardiotoxicity increases mortality after myocardial infarction.

Authors:  Jason M Duran; Catherine A Makarewich; Danielle Trappanese; Polina Gross; Sharmeen Husain; Jonathan Dunn; Hind Lal; Thomas E Sharp; Timothy Starosta; Ronald J Vagnozzi; Remus M Berretta; Mary Barbe; Daohai Yu; Erhe Gao; Hajime Kubo; Thomas Force; Steven R Houser
Journal:  Circ Res       Date:  2014-04-09       Impact factor: 17.367

2.  Sorafenib-associated multivessel coronary artery vasospasm.

Authors:  T Naib; R M Steingart; C L Chen
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

3.  Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.

Authors:  Linda Calistri; Cesare Cordopatri; Cosimo Nardi; Elena Gianni; Fabio Marra; Stefano Colagrande
Journal:  Mol Clin Oncol       Date:  2017-01-16

4.  Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.

Authors:  Hassan Shawa; Naifa L Busaidy; Dawid Schellingerhout; Mouhammed Amir Habra
Journal:  BMJ Case Rep       Date:  2013-05-15

Review 5.  Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?

Authors:  Joerg Herrmann
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

Review 6.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

7.  Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.

Authors:  Akihiro Yamasaki; Narihiro Umeno; Shigeru Harada; Kosuke Tanaka; Masaki Kato; Kazuhiro Kotoh
Journal:  J Gastrointest Oncol       Date:  2016-06

8.  Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.

Authors:  Maria Abbondanza Pantaleo; Anna Mandrioli; Maristella Saponara; Margherita Nannini; Giovanna Erente; Cristian Lolli; Guido Biasco
Journal:  BMC Cancer       Date:  2012-06-11       Impact factor: 4.430

Review 9.  Optimal management of coronary artery disease in cancer patients.

Authors:  Xue-Jie Han; Jian-Qiang Li; Zulfiia Khannanova; Yue Li
Journal:  Chronic Dis Transl Med       Date:  2020-01-14

Review 10.  Cardiotoxic effects of angiogenesis inhibitors.

Authors:  Stephen J H Dobbin; Mark C Petrie; Rachel C Myles; Rhian M Touyz; Ninian N Lang
Journal:  Clin Sci (Lond)       Date:  2021-01-15       Impact factor: 6.124

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.